Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development

Infection with Plasmodium falciparum and vivax cause most cases of malaria. Emerging resistance to current antimalarial medications makes new drug development imperative. Ideally a new antimalarial drug should treat both falciparum and vivax malaria. Because malaria parasites are purine auxotrophic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Deniskin, Roman, Frame, I.J., Sosa, Yvett, Akabas, Myles H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706624/
https://www.ncbi.nlm.nih.gov/pubmed/26862473
http://dx.doi.org/10.1016/j.ijpddr.2015.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706624/
https://www.ncbi.nlm.nih.gov/pubmed/26862473
http://dx.doi.org/10.1016/j.ijpddr.2015.11.003

Ejemplares similares